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It is unclear why motor neurons selectively degenerate in amyotrophic lateral sclerosis (ALS). Saxena et al.
(2013) demonstrate that excitation of motor neurons can prevent their demise in a mouse model of inherited
ALS by a mechanism involving the mTOR pathway.People with amyotrophic lateral sclerosis
(ALS) suffer progressive weakness, paral-
ysis, and death as a result of the dysfunc-
tion and degeneration of lower and upper
motor neurons (MNs).While inmost cases
the causes of ALS are unknown, for some
an inherited genetic defect is responsible.
Mutations that cause familial ALS (FALS)
include those in genes encoding super-
oxide dismutase 1 (SOD1), TDP-43,
Ubiquilin-2 and FUS, and a hexanucle-
otide repeat in a noncoding region on
chromosome 9 (C9orf72) (Turner et al.,
2013). Transgenic mice expressing
mutant human SOD1 (mutSOD1) are a
widely used ALS model as they develop
progressive MN degeneration and
paralysis similar to ALS patients. MNs in
mutSOD1mice accumulate SOD1 protein
aggregates and exhibit mitochondrial
dysfunction.
Studies of ALS patients and animal
models suggest thatMNsmay suffer exci-
totoxicity, a neurodegenerative process
involving excessive activation of gluta-
mate receptors and cellular Ca2+ over-
load. Impaired uptake of glutamate by
astrocytes may contribute to excito-
toxicity in ALS, and currently the only
drug that has demonstrated a disease-
modifying effect in ALS patients is
believed to act by reducing excitation of
MNs (Rothstein, 2009). Surprisingly,
Saxena et al. (2013) nowprovide evidence
that moderate levels of glutamate re-
ceptor activation can counteract neuro-
degenerative processes in SOD1 ALS
mouse models. Pharmacological inhibi-
tion of AMPA and NMDA receptors in
transgenic mice overexpressing wild-
type human SOD1 (these mice usually
develop only mild MN pathology late in
life) resulted in endoplasmic reticulum
(ER) stress and accumulation ofmisfoldedSOD1 in MNs. Conversely, treatment with
AMPA reduced SOD1 accumulation. ER
stress induced by tunicamycin or thapsi-
gargin was sufficient to cause the selec-
tive accumulation of SOD1 aggregates in
MNs of mutSOD1 mice but not in other
neuronal populations examined. Thus,
MNs in mutSOD1 mice are exceptionally
vulnerable to ER stress, and its con-
sequences can be mitigated by mode-
rate activation of glutamate receptors
and exacerbated by glutamate receptor
inhibition.
Not all subpopulations of MNs are
equally vulnerable to degeneration in
ALS; larger MNs in the spinal cord
typically degenerate early in the course
of the disease, whereas smaller cranial
MNs are relatively resistant. Differences
in cellular Ca2+ handling systems and
consequent vulnerability to excitotoxicity
may contribute to selective MN vulnera-
bility because MNs with higher levels of
Ca2+-binding proteins (CBPs) such as
calbindin, parvalbumin, and the ER CBP
calteticulin are more resistant than MNs
with low levels of these CBPs (Bernard-
Marissal et al., 2012). Differences in the
expression or function of glutamate and
GABA receptors, glial glutamate trans-
porters, mitochondrial proteins, and ER
stress and Ca2+-regulating proteins also
affect MN vulnerability (Boille´e et al.,
2006). In mutSOD1 mice, fast fatiguing
(FF) MNs with low excitability that inner-
vate hind leg muscles succumb first,
followed by medium excitability fatigue-
resistant MNs; highly excitable MNs are
relatively resistant. Saxena et al. (2013)
found that CNQX accelerated muscle
denervation and death of mutSOD1 mice
but had no discernible effects in trans-
genic mice expressing wild-type SOD1.
AMPA treatment significantly delayedNeuronMN degeneration and extended survival
of mutSOD1 mice. However, whereas
fatigue-resistant MNs and highly excit-
able MNs were protected by AMPA, FF
MNs were not substantially protected,
indicating that AMPA receptor activa-
tion is less beneficial for the most vulner-
able MNs.
To determine whether direct activation
of MNs enhances their resistance to
mutant SOD1, Saxena et al. (2013)
employed pharmacologically selective
actuator module (PSAM) technology to
depolarize or hyperpolarize only MNs in
mutSOD1 mice. This was accom-
plished using adeno-associated virus
vectors to express the 5HT3 receptor
(depolarization) or glycine receptor
(hyperpolarization) in either MNs or
parvalbumin-expressing interneurons on
one side of the spinal cord. They found
that under conditions expected to
increase MN excitability, amounts of
aggregated SOD1 and GRP78/Bip were
reduced in the MNs, suggesting reduced
ER stress.
At first blush, the new findings (Saxena
et al., 2013) appear to directly contradict
the excitotoxicity hypothesis of ALS.
MNs are vulnerable to AMPA receptor-
mediated excitotoxicity and mutSOD1
increases the vulnerability of MNs to exci-
totoxicity by inducing oxidative stress and
mitochondrial dysfunction and by impair-
ing glutamate transport in astrocytes
(Kruman et al., 1999; Boille´e et al., 2006).
Moreover, intrathecal infusion of a blocker
of Ca2+-permeable AMPA channels can
retard MN degeneration in rats express-
ing mutant SOD1 (Yin et al., 2007).
However, many biological systems
exhibit a biphasic dose response to envi-
ronmental stimuli, such that low levels of
exposure are beneficial, whereas high80, October 2, 2013 ª2013 Elsevier Inc. 1
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Figure 1. Mechanisms by which Glutamate Receptor-Mediated Excitation May Protect Motor Neurons against SOD1 Mutations that Cause
Inherited ALS
CaMK, Ca2+/calmodulin-dependent protein kinase; CREB, cyclic AMP response element-binding protein; ER, endoplasmic reticulum; IL-1b, interleukin-1b;
mTOR, mammalian target of rapamycin; NPP, neuroprotective proteins; SV, synaptic vesicle; TNFa, tumor necrosis factor a; VDCC, voltage-dependent Ca2+
channel.
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Previewslevels of exposure are damaging, a
phenomenon called hormesis that could
explain both the ability of AMPA receptor
activation to protect MNs (Saxena et al.,
2013) and an excitotoxic mechanism of
MN death in ALS (Figure 1). Indeed,
activation of kinases and transcription
factors such as CREB and NF-kB by the
Ca2+ influx resulting from synaptic gluta-
mate receptor activation can upregulate
neurotrophic factors, Ca2+ handling
proteins, antioxidant systems, protein
chaperones, and DNA repair enzymes
(Stranahan and Mattson, 2012).
Calreticulin plays an important role in
‘‘sensing’’ ER Ca2+ levels and is a protein
chaperone that can protect cells against
ER stress. Saxena et al. (2013) found
that levels of calreticulin were reduced in
MNs of mutSOD1 mice and that AMPA2 Neuron 80, October 2, 2013 ª2013 Elsevierreceptor activation increased calreticulin
levels. Three other cellular stress re-
sponse proteins that were affected by
AMPA receptor activation and inhibition
in MNs of mutSOD1 mice were GRP-
78, DREAM/calsenilin, and GADD45b.
GRP78 levels were elevated in mutant
SOD1 MNs, and experimental enhance-
ment of MN excitability reduced GRP78
levels, suggesting that excitation can
reduce ER stress. However, GRP78 can
protect neurons against excitotoxicity
(Yu et al., 1999) and so it might be ex-
pected that a reduction in GRP78 levels
in response to AMPA receptor activa-
tion would increase the vulnerability of
MNs to excitotoxicity. DREAM levels
were reduced in MNs of mutSOD1 mice
and AMPA receptor activation elevated
DREAM levels (Saxena et al., 2013).Inc.Elevation of DREAM levels in response
to AMPA receptor activation may or may
not be neuroprotective as DREAM can
either protect against excitotoxicity or
promote cell death, depending upon the
cell type examined (Lilliehook et al.,
2002). Levels of GADD45b were elevated
in MNs of FALS mice, and blockade of
AMPA receptors reduced GADD45b
levels, although it is not clear how these
changes in GADD45b levels affect MN
vulnerability. Thus, while AMPA receptor
activation can modify several stress-
responsive pathways, further work is
required to establish which of these (or
others not studied) mediate the neuro-
protective effects of activity in mutSOD1
mice.
The mammalian target of rapamycin
(mTOR) protein plays a fundamental role
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Previewsin adjusting cell metabolism and growth
to the availability of nutrients such as
glucose and amino acids, which may be
particularly important in MNs because of
their large size and high metabolic
demand. When energy and amino acids
are plentiful, mTOR is active and stimu-
lates protein synthesis. Activation of
mTOR also reduces autophagy, a mecha-
nism by which cells remove protein
aggregates and damaged organelles by
targeting them to lysosomes (Nixon,
2013). Inhibitors of mTOR such as rapa-
mycin have recently been tested for their
potential therapeutic application to a
range of neurodegenerative disorders,
with reported benefits in animal models
of Huntington’s and Parkinson’s diseases
(Sarkar et al., 2009). Similar to a previous
study (Zhang et al., 2011), when Saxena
et al. (2013) treated mutSOD1 mice with
rapamycin, the ALS disease process
was exacerbated. Moreover, treatment
of mutSOD1 mice with oxotremorine to
stimulate mTOR and salubrinal to inhibit
ER stress greatly slowed MN degenera-
tion and extended survival of the mice.
These and additional findings suggest
that moderate levels of glutamate recep-
tor activation can engage adaptive
cellular stress response pathways that
suppress mutant SOD aggregation and
enhancemTOR-mediated protein synthe-
sis to sustain MN survival.
It remains to be determined whether
enhancing activity in MNs can also coun-
teract the pathogenic processes in more
common forms of FALS not caused by
an SOD1mutation. In contrast to sporadic
ALS and FALS caused by C9orf72 and
TDP-43 mutations, MNs affected by
SOD1 mutations do not exhibit TDP-43
pathology (Turner et al., 2013). Moreover,there is evidence that impaired autophagy
maycontribute to accumulationof TDP-43
in neurons (Wang et al., 2012) and that
rapamycin can ameliorate such TDP-43
neuropathology (Caccamo et al., 2009).
For reasons as yet unknown, MNs in the
mutSOD1mice appear not tobeadversely
affected when autophagy is downregu-
lated by mTOR activation (Saxena et al.,
2013). Why might activation of mTOR be
beneficial forMNs inmutSOD1mice,while
inhibition of mTOR is beneficial in
several other neurodegenerative disorder
models? One possibility is that MNs
require higher levels of protein synthesis
and can better tolerate reduced levels of
autophagy compared to neurons affected
in other neurodegenerative disorders.
Finally, the new findings touch upon the
practical issue of whether exercise/
activity is beneficial or detrimental to
MNs in the setting of ALS. Considerable
evidence suggests that exercise stimu-
lates neurotrophic factor production and
is neuroprotective for some populations
of neurons (Stranahan and Mattson,
2012). However, some epidemiological
data suggest that elite athletes in sports
that require extensive exertion are at
increased risk for ALS. The hormesis
paradigm provides a parsimonious expla-
nation whereby moderate levels of MN
excitation stimulates neurotrophic and
protein biosynthetic pathways that pro-
tect against ALS, while higher levels of
excitation may result in degeneration of
theMNs, particularly in genetically predis-
posed individuals.ACKNOWLEDGMENTS
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